Jagsonpal Pharmaceuticals Intrinsic Value
Jagsonpal Pharmaceuticals (JAGSNPHARM) median intrinsic value is ₹424.62 from 9 valuation models (range ₹66–₹554), vs current price ₹221.61 — +91.6% upside (Trading Below Calculated Value), margin of safety 47.8%. Read JAGSNPHARM dividend payout details for the complete payout history and dividend yield track record.
JAGSNPHARM Valuation Methods Summary — DCF, Graham Number & P/E
Jagsonpal Pharmaceuticals intrinsic value across 9 models vs current price ₹221.61 — upside/downside and value range per method. For current market price and key ratios, visit Jagsonpal Pharmaceuticals stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹140.80 | ₹112.64 - ₹168.96 | -36.5% | EPS: ₹6.40, Sector P/E: 22x |
| Book Value Method | asset | ₹424.62 | ₹382.16 - ₹467.08 | +91.6% | Book Value/Share: ₹212.31, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹441.54 | ₹397.39 - ₹485.69 | +99.2% | Revenue/Share: ₹220.77, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹430.77 | ₹387.69 - ₹473.85 | +94.4% | EBITDA: ₹56.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹554.03 | ₹443.22 - ₹664.84 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹66.48 | ₹59.83 - ₹73.13 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹99.24 | ₹89.32 - ₹109.16 | -55.2% | Revenue Growth: 6.8%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹443.22 | ₹398.90 - ₹487.54 | +100.0% | ROE: 15.9%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹174.85 | ₹157.37 - ₹192.34 | -21.1% | EPS: ₹6.40, BVPS: ₹212.31 |
JAGSNPHARM Intrinsic Value vs Market Price — All Valuation Models
Jagsonpal Pharmaceuticals fair value range ₹66–₹554 vs current market price ₹221.61 across 9 valuation models. Analyse Jagsonpal Pharmaceuticals ownership structure to track promoter, FII and institutional holdings.
JAGSNPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
Jagsonpal Pharmaceuticals median intrinsic value ₹424.62, current price ₹221.61 — Trading Below Calculated Value by 91.6%, margin of safety 47.8%.
What is the intrinsic value of JAGSNPHARM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Jagsonpal Pharmaceuticals (JAGSNPHARM) is ₹424.62 (median value). With the current market price of ₹221.61, this represents a +91.6% variance from our estimated fair value.
The valuation range spans from ₹66.48 to ₹554.03, indicating ₹66.48 - ₹554.03.
Is JAGSNPHARM undervalued or overvalued?
Based on our multi-method analysis, Jagsonpal Pharmaceuticals (JAGSNPHARM) appears to be trading below calculated value by approximately 91.6%.
JAGSNPHARM Financial Health — Key Ratios vs Industry Benchmarks
Jagsonpal Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 11.92 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 15.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 20.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.91x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
JAGSNPHARM Cash Flow Quality — Operating & Free Cash Flow
Jagsonpal Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹55 Cr | ₹33 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹35 Cr | ₹23 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹47 Cr | ₹18 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹7 Cr | ₹-6 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹28 Cr | ₹27 Cr | Positive Free Cash Flow | 8/10 |